相互作用
Factor viii + Marstacimab
重症度: 重大
Factor viii and Marstacimab: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Marstacimab inhibits tissue factor pathway inhibitor and raises hemostatic potential, and adding factor VIII concentrates may further increase the risk of thromboembolic events. Factor VIII used for prophylaxis should be discontinued before starting marstacimab.
この相互作用をわかりやすく説明すると
Factor viii and Marstacimab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Factor viii belongs to Cardiovascular; Marstacimab belongs to Cardiovascular.
なぜ起こるのか
Additive procoagulant pharmacodynamic effects of TFPI inhibition and exogenous factor VIII.
対処法
Stop factor VIII prophylaxis before starting marstacimab, and use the lowest effective factor VIII dose only for breakthrough bleeds. Monitor for signs of thrombosis.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Factor viiiとMarstacimabの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を7日間無料でお試し。カード登録不要。
Factor viiiのその他の相互作用
よくある質問
Can I take Factor viii with Marstacimab?
MediHelp rates the interaction as major. Factor viii and Marstacimab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Marstacimab inhibits tissue factor pathway inhibitor and raises hemostatic potential, and adding factor VIII concentrates may further increase the risk of thromboembolic events. Factor VIII used for prophylaxis should be discontinued before starting marstacimab.
How serious is the interaction between Factor viii and Marstacimab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop factor VIII prophylaxis before starting marstacimab, and use the lowest effective factor VIII dose only for breakthrough bleeds. Monitor for signs of thrombosis.
What other medicines interact with Factor viii?
MediHelp also lists interactions of Factor viii with, for example, Concizumab. The full list is on the Factor viii page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
